Views & Analysis What HCPs say about Roche's breast cancer drug The online conversations about breast cancer drug Kadcyla before it was approved by NICE.
News Biosimilars manufacturers close in on Roche cancer blockbust... FDA panel backs Herceptin and Avastin biosimilars.
News Angle poised to take on US cancer diagnostics market Circulating tumour cell test could help select drug therapy.
News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
